What Zomacton Treats
Zomacton (somatropin) is a recombinant human growth hormone used to treat growth hormone deficiency (GHD) in children and adults. In children, it addresses short stature from GHD, Turner syndrome, Prader-Willi syndrome, chronic kidney disease before transplant, or idiopathic short stature. In adults, it replaces deficient growth hormone due to pituitary disease, hypothalamic disease, surgery, radiation, or trauma.[1]
How Zomacton Works
It mimics natural growth hormone produced by the pituitary gland, stimulating growth in bones and tissues, increasing muscle mass, reducing fat, and boosting metabolism. Administered via subcutaneous injection, typically daily.[1]
Common Dosage and Administration
Dosing varies by condition and age: children with GHD get 0.16-0.24 mg/kg/week divided into daily doses; adults start at 0.2-0.3 mg/day, adjusted based on IGF-1 levels. Use Ferring's pen device or standard syringes.[1]
Who Makes Zomacton and Approval Status
Ferring Pharmaceuticals manufactures Zomacton. FDA approved it in 2014 for pediatric GHD, with expansions for other uses. It's a follow-on biologic to earlier somatropins like Genotropin.[1]
When Does Zomacton Patent Expire?
Key patents cover formulations and devices; U.S. Patent 8,119,601 (pen injector) expires around 2028, while others like 7,615,532 (for stability) end earlier in 2025. Check DrugPatentWatch.com for litigation updates and exact expiry dates, as challenges could accelerate generic entry.[2]
Zomacton vs. Other Growth Hormones
Compared to Norditropin (Novo Nordisk) or Humatrope (Lilly), Zomacton has similar efficacy but stands out with a needle-free device option, potentially improving adherence. All carry black-box warnings for increased mortality risk in critically ill patients.[1]
Key Side Effects and Risks
Common issues include injection-site reactions, joint/muscle pain, swelling, and headaches. Serious risks: diabetes worsening, intracranial hypertension, scoliosis progression in kids, and cancer growth promotion. Monitor thyroid, glucose, and IGF-1 levels. Not for active malignancy or critical illness.[1]
Cost and Access
Monthly cost ranges $1,000-$2,000 without insurance, depending on dose. Patient assistance programs from Ferring help eligible users.[1]
[1]: FDA Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203488s017lbl.pdf
[2]: DrugPatentWatch.com - https://www.drugpatentwatch.com/p/tradename/ZOMACTON